Korea's 37th homegrown new drug for gastroesophageal reflux disease, Ja Q Bo (ingredient name: zaztaprozan), has been released in an orally disintegrating tablet (ODT) formulation that can be taken without water.
JEIL PHARMACEUTICAL said on the 6th that it launched "Ja Q Bo orally disintegrating tablet 20 mg (ingredient name: zaztaprozan citrate)" on the 1st, developed by its subsidiary Onconic Therapeutics.
The Ja Q Bo orally disintegrating tablet is an expanded formulation of "Ja Q Bo tablet," which was released in Oct. last year. As an orally disintegrating tablet that dissolves in the mouth without water, it considers dosing convenience for patients with dysphagia who have difficulty swallowing pills and for older patients. Unlike the existing pink film-coated tablet, it is a white round tablet with an orange flavor.
The Ja Q Bo orally disintegrating tablet adds a waterless dosing option while maintaining the existing Ja Q Bo tablet's features of rapid onset, long duration, and dosing regardless of meals.
Ja Q Bo is currently used to treat erosive gastroesophageal reflux disease, and coverage under the national health insurance for the gastric ulcer indication is also planned. JEIL PHARMACEUTICAL plans to widen its prescription range in the anti-peptic ulcer market through this ODT launch and the expanded indication.
A JEIL PHARMACEUTICAL official said, "We expanded formulation choices by adding an orally disintegrating tablet 15 months after the launch of Ja Q Bo," and added, "If coverage is added for the gastric ulcer indication going forward, we expect stronger prescription competitiveness."